Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:09:48 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:VNDA - VANDA PHARMACE INC - https://www.vandapharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VNDA - Q0.27.50·8.700.37.57+0.344.71,089.87,7728,6297.37  7.72  7.309.60  3.809219:19:28Feb 0415 min RT 2¢

Recent Trades - Last 10 of 8629
Time ETExPriceChangeVolume
19:19:28Q7.630.405
18:07:59Q7.500.271
18:07:36Q7.500.2772
18:07:30Q7.500.271
18:07:18Q7.500.271
18:05:58Q7.51190.28191
18:05:42Q7.51190.28191
18:04:35Q7.51190.28191
18:04:21Q7.51190.28191
18:03:00Q7.51190.28191

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-04 18:01U:VNDANews ReleaseVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
2026-01-08 07:00U:VNDANews ReleaseVanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ(TM) Supplemental New Drug Application for Jet Lag Disorder
2025-12-30 18:13U:VNDANews ReleaseVanda Pharmaceuticals Announces FDA Approval of NEREUS(TM) (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
2025-12-15 07:00U:VNDANews ReleaseVanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
2025-12-11 17:02U:VNDANews ReleaseVanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
2025-12-04 16:21U:VNDANews ReleaseFDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
2025-11-28 07:00U:VNDANews ReleaseVanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
2025-11-17 18:30U:VNDANews ReleaseVanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
2025-11-05 17:00U:VNDANews ReleaseVanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
2025-10-29 16:01U:VNDANews ReleaseVanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
2025-10-22 16:30U:VNDANews ReleaseVanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
2025-10-08 08:00U:VNDANews ReleaseMonumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena
2025-10-01 17:02U:VNDANews ReleaseVanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
2025-09-25 08:00U:VNDANews ReleaseVanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ(TM)) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"
2025-08-28 17:23U:VNDANews ReleaseVanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences
2025-08-28 07:00U:VNDANews ReleaseVanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera
2025-08-18 07:00U:VNDANews ReleaseIn a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder
2025-07-31 07:30U:VNDANews ReleaseVanda Pharmaceuticals Reports Second Quarter 2025 Financial Results
2025-07-23 16:30U:VNDANews ReleaseVanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025
2025-06-10 08:00U:VNDANews ReleaseVanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S